Business Context and Reporting Period
This Form 8-K was filed by Corvus Pharmaceuticals, Inc. on December 7, 2016. The report details corporate governance actions taken by the Board of Directors regarding executive compensation adjustments effective for the 2017 fiscal year.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation adjustments.
Material Changes
The Board approved increases to 2017 annual salaries and new stock option awards for four executive officers. The stock options vest in equal monthly installments over 48 months, subject to continued service.
| Executive Officer | 2017 Annual Salary | Stock Option Award (Shares) |
|---|---|---|
| Richard A. Miller, M.D. (CEO) | $300,000 | 160,000 |
| Leiv Lea (CFO) | $291,500 | 25,000 |
| William B. Jones, Ph.D. (VP, Pharmaceutical Development) | $265,000 | 25,000 |
| Erik J. Verner, Ph.D. (VP, Chemistry Research) | $250,000 | 25,000 |
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of risks and contingencies. The stock option exercise price is set equal to the closing price of the Company's common stock on The NASDAQ Global Market on the date of grant (December 7, 2016).
Investor Verification Points
- Verify the closing stock price on December 7, 2016, to determine the exercise price for the granted options.
- Confirm the total number of shares authorized under the 2016 Equity Incentive Award Plan to assess dilution impact.
- Review prior year compensation to quantify the specific percentage increase in salaries.